Skip to content
Politically.com Search all
Menu

2025 · 2nd Quarter (Apr 1 - June 30)

NOVARTIS, INC.

Filed by TODD STRATEGY GROUP.

Open official filing
Source: Lobbying Disclosure APIRecently refreshed. 2026-08-03 06:26:15 UTC.

Source-reported fields

Filing overview

Type
2nd Quarter - Report
Posted
Jul 20, 2025
Income
$60,000.00
Expenses
Not reported
Filing UUID
dffdf7aa-bfbc-4e2d-8e4c-c73de30edfd2
Termination date
Not reported

Literal source text

Lobbying issues and bill citations

MMM · Medicare/Medicaid

Center for Medicare and Medicaid Innovation (CMMI) policy issues. Drug Pricing. General Medicare and Medicaid Issues. Implementation of Inflation Reduction Act of 2022. H.R.1672 - Maintaining Investments in New Innovation Act. S.3131 / H.R.5539 - ORPHAN Cures Act. S.832 - EPIC Act of 2025.

Literal federal measure citations: H.R.1672, S.3131, H.R.5539, S.832

TAR · Tariff (miscellaneous tariff bills)

Traffic policies.

HCR · Health Issues

Supply Chain. 340B Issues. Outcomes based contracting/value-based arrangements. Genetically Targeted Therapies. PBM policy issues. H.R.5376 - Inflation Reduction Act of 2022 implementation.

Literal federal measure citations: H.R.5376

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.